Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor
- 28 June 2001
- journal article
- Published by Springer Nature in Oncogene
- Vol. 20 (29) , 3845-3856
- https://doi.org/10.1038/sj.onc.1204531
Abstract
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes. Oncogene also publishes 8 Reviews issues a year, on a broad range of topics.Keywords
This publication has 27 references indexed in Scilit:
- c-Abl Has High Intrinsic Tyrosine Kinase Activity That Is Stimulated by Mutation of the Src Homology 3 Domain and by Autophosphorylation at Two Distinct Regulatory TyrosinesJournal of Biological Chemistry, 2000
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Epidermal Growth Factor Receptor Signaling Activates Met in Human Anaplastic Thyroid Carcinoma CellsExperimental Cell Research, 2000
- Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571Oncogene, 2000
- Hepatocyte growth factor/scatter factor‐induced intracellular signallingInternational Journal of Experimental Pathology, 2000
- Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemiaJournal of Clinical Investigation, 2000
- Signaling to Rho GTPasesExperimental Cell Research, 1999
- Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancerCritical Reviews in Oncology/Hematology, 1999
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996
- c-Kit Proto-oncogene Is More Likely to Lose Expression in Differentiated Thyroid Carcinoma Than Three Thyroid-specific Genes: Thyroid Peroxidase, Thyroglobulin, and Thyroid Stimulating Hormone Receptor.Endocrine Journal, 1995